Considerations when selecting a genomic test to use in specific breast cancer patients - European Medical Journal

Considerations when selecting a genomic test to use in specific breast cancer patients

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains that the use of genomic tests for breast cancer patients in clinical practice is affected by numerous factors, including the ability of the test to predict response to treatment and the ability of the test to provide meaningful prognostic information in addition to the information provided by clinicopathologic tools.

This content is supported by Genomic Health, Inc.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>